文献速递小儿泌尿与泌尿修复

低剂量人绒毛膜促性腺激素刺激试验作为膀胱外翻-尿道上裂复合体男孩尿失禁预后指标

Low-dose Human Chorionic Gonadotropin Stimulation Test as a Prognostic Incontinent Indicator in Boys With Bladder Exstrophy-epispadias Complex.
PubMed 文献 · Urology · 2016-12-27

前瞻性纳入30例膀胱外翻-尿道上裂复合体(BEEC)伴尿失禁男孩,随机分为低剂量人绒毛膜促性腺激素(HCG)组(250 IU 肌注,每周3次,共4周)与对照组各15例,平均随访4年。HCG组尿失禁评分改善显著更高(P=.01),总前列腺体积(P<.0001)和膀胱容量(P<.0001)显著增加。作者初步结论提示低剂量HCG可能对BEEC伴尿失禁男孩有作用,前列腺增大与尿失禁改善相关。

要点

  • 低剂量HCG组尿失禁评分改善显著高于对照组(P=.01)。
  • HCG组总前列腺体积(P<.0001)与膀胱容量(P<.0001)均显著增加。
  • HCG给药后未见重大副作用,无需开放手术膀胱颈重建。

核心结论

  • 作者初步结果提示低剂量HCG对BEEC伴尿失禁男孩可能具有作用。
  • 数据还揭示前列腺增大在尿失禁改善中的作用。
  • 长期HCG治疗增加膀胱容量,可能有助于未来重建手术。

研究设计与样本

  • 前瞻性研究,纳入30例BEEC伴尿失禁男孩,中位年龄7.5岁,随机分为2组。
  • HCG组给予250 IU HCG肌内注射,每周3次,持续4周;另15例为对照组。
  • 平均随访4年,采用3D超声或盆腔磁共振成像及尿流率检查评估。

主要发现

  • HCG组尿失禁评分改善显著高于对照组(P=.01)。
  • 患者及家长的健康相关生活质量评分在末次随访时均显著升高(P<.001)。
  • HCG组所有患者总前列腺体积(P<.0001)和膀胱容量(P<.0001)均显著增加。
  • 基础血清睾酮水平在首次(P=.001)和末次(P<.001)注射后显著升高,末次注射后3个月无显著升高(P>.05)。
  • HCG给药后未见重大副作用,无需开放手术膀胱颈重建。

临床怎么用

  • 作者初步结果提示低剂量HCG在BEEC伴尿失禁男孩中可能具有作用。
  • 作者指出前列腺增大与尿失禁改善相关。
  • 作者指出长期HCG治疗增加膀胱容量,可能有助于未来重建手术。

局限性

  • 作者称其为初步结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the effect of low-dose human chorionic gonadotropin (HCG) administration on structural changes in the lower urinary tract in boys with urinary incontinence in the setting of bladder exstrophy-epispadias complex (BEEC). PATIENTS AND METHODS: We prospectively evaluated 30 patients (median age 7.5 years) with BEEC and randomly divided them into 2 groups. Patients in the HCG group were administered 250 IU HCG intramuscularly 3 times per week during a 4-week period. The other 15 patients served as the control group. The patients were followed up for a mean duration of 4 years. Incontinence rate, hormonal changes, penile length, prostate size, and bladder capacity were evaluated using 3D sonography or pelvic magnetic resonance imaging and uroflowmetry studies before and after HCG administration. RESULTS: The incontinence score improvement was significantly higher in the HCG group (P = .01). A significant increase was detected in the health-related quality of life score of both patients and parents at the final follow-up (P < .001). The total prostate size (P < .0001) and bladder capacity (P < .0001) increased significantly in all patients of the HCG group. Basal serum testosterone level increased significantly after the first (P = .001) and last (P < .001) injections with no significant increase 3 months after the last injection (P > .05). No major side effect was found following the administration of HCG, with no need for open surgical bladder neck reconstruction. CONCLUSION: Our preliminary results suggest the role of low-dose HCG in boys with BEEC suffering from urinary incontinence. The data also reveal the role of prostate enlargement in the improvement of urinary incontinence. Chronic treatment with HCG increases bladder capacity that may facilitate future reconstructive surgery.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Sabetkish N, Eftekharzadeh S, Elmi A, et al. Low-dose Human Chorionic Gonadotropin Stimulation Test as a Prognostic Incontinent Indicator in Boys With Bladder Exstrophy-epispadias Complex. Urology. 2016. PMID: 28039050. doi:10.1016/j.urology.2016.12.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。